Mr. Donald Hayden is an angel investor. He serves as Chief Executive Officer & Chairman at WindMIL Therapeutics. He serves as a Senior Advisor at Prospect Venture Partners. He served as the Chairman at Nora Therapeutics. He brings to Prospect the experiences and perspective resulting from a highly-successful 25-year career with Bristol-Myers Squibb Company as well as the insights gained from key roles at a number of smaller, more entrepreneurial pharmaceutical and biotech companies over the past 5 years. At Bristol-Myers Squibb, Mr. Hayden served as President of Global Pharmaceuticals; Executive Vice President and President, Americas, overseeing two major pharmaceutical units and two healthcare businesses; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals and Nora Therapeutics. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University. He also serves as the Board member at Satori Pharmaceuticals and Chairman of Vitae Pharmaceuticals.